Skip to content
This GLP
← Research
Evidence

A 310-fold increase from almost nothing

GLP-1 prescriptions to children aged 8 to 11 rose 310-fold in seven years, from a base of 0.03%. The children getting them are the least socially vulnerable.

Dana Sullivan6 min read
Prescriptions per 10,000 children with obesityage79.5 (11 years)41.5 (8 years)sex75.9 (girls)42.8 (boys)social vulnerability76.1 (low)49.2 (high)With an obesity-related condition: 188.9 per 10,000.

Nothing on this site can be bought for a child — every seller in this roster serves adults only, and a prescription for an eight-year-old comes from a pediatrician, not a subscription form. The study is here because the growth figure attached to it is going to be quoted without its base, which is how most real-world prescribing data gets used.

The headline and the base

Prescribing to this age group rose 310-fold between 2019 and 2026. [1] The starting point was 0.03% of children, so the multiplier is doing what a multiplier does to a very small number.

Across the whole cohort of 3.5 million children, 0.6% ever received a prescription. That is uncommon by any reading.

Who is getting them

Older children more than younger: 79.5 per 10,000 at age eleven against 41.5 at age eight. Girls more than boys: 75.9 against 42.8. The paper does not explain the second gap and neither will this page.

The largest difference is clinical. Children who already had an obesity-related condition were prescribed at 188.9 per 10,000, which the authors read as clinicians reserving these drugs for the highest cardiometabolic risk. That looks like appropriate targeting, and it is the same logic as an eligibility threshold applied by judgment rather than by rule.

The finding that runs the wrong way

Children with less social vulnerability received more prescriptions: 76.1 per 10,000 against 49.2 among the most vulnerable.

Childhood obesity is commoner, not rarer, in the groups getting fewer prescriptions. So access here is tracking resources rather than need, which is the ordinary pattern for an expensive drug and is worth naming when the figure appears inside a paper about prescribing trends.

What it means for an adult reader

Two things, neither of them about children. The first is that a fold-change is not a prevalence, and any number of that shape should send you looking for the base.

The second is that who gets a prescription is decided by cost and coverage as much as by clinical need, which is visible in how few eligible adults ever receive one and in where sellers will and will not ship.

Frequently asked

How many young children are on these drugs?
Few. Across 3,520,531 children aged 8 to 11 with obesity and no diabetes, 0.6% ever received a prescription between 2019 and 2026.
What does a 310-fold increase mean?
That prevalent prescribing went from 0.03% in 2019 to 9.3% in 2026. The multiplier is large because the starting number was very small.
Who is most likely to be prescribed one?
Children who already have an obesity-related condition, at 188.9 per 10,000 — well above the rate for any other group measured.
Can I buy one for my child from a telehealth seller?
No. Every seller covered on this site serves adults only. Prescribing at this age happens through pediatric care.

Sources

  1. [1] Orandi BJ, et al. (2026). Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026 Pediatrics. PMID 42692477

Where to get it

Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

Compare providers →

More in Evidence